Video

Dr. Markman Discusses the Olaparib Phase II Trial

Author(s):

Maurie Markman, MD

Dr. Markman Discusses the Olaparib Phase II Trial

Maurie Markman, MD the National Director for Medical Oncology for the Cancer Treatment Centers of America Discusses the Olaparib Phase II Trial

Related Videos
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Related Content
Whitney Goldsberry, MD
November 21st 2024

Olaparib Leads PARP Inhibitor Charge in the Treatment of BRCA-Mutated, HRD Ovarian Cancer

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Toon Van Gorp, MD
November 18th 2024

European Commission Approves Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Gynecologic Oncology
November 14th 2024

Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers

Ron Bentsur, chairman and CEO of Nuvectis Pharma
November 14th 2024

NXP800 Demonstrates Single-Agent Activity in ARID1a+ Platinum-Resistant Ovarian Cancer